Vectus Biosystems Ltd - Asset Resilience Ratio
Vectus Biosystems Ltd (VBS) has an Asset Resilience Ratio of 2.18% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VBS strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2020)
This chart shows how Vectus Biosystems Ltd's Asset Resilience Ratio has changed over time. See Vectus Biosystems Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Vectus Biosystems Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vectus Biosystems Ltd (VBS) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$70.00K | 2.18% |
| Total Liquid Assets | AU$70.00K | 2.18% |
Asset Resilience Insights
- Limited Liquidity: Vectus Biosystems Ltd maintains only 2.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vectus Biosystems Ltd Industry Peers by Asset Resilience Ratio
Compare Vectus Biosystems Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Vectus Biosystems Ltd (2013–2020)
The table below shows the annual Asset Resilience Ratio data for Vectus Biosystems Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-06-30 | 90.60% | AU$2.72 Million ≈ $1.92 Million |
AU$3.00 Million ≈ $2.12 Million |
+4.48pp |
| 2016-06-30 | 86.11% | AU$4.03 Million ≈ $2.85 Million |
AU$4.68 Million ≈ $3.31 Million |
+85.82pp |
| 2015-06-30 | 0.29% | AU$33.99K ≈ $24.05K |
AU$11.73 Million ≈ $8.30 Million |
-77.53pp |
| 2013-06-30 | 77.82% | AU$1.16 Million ≈ $821.49K |
AU$1.49 Million ≈ $1.06 Million |
-- |
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more